Elevated endothelin-1 vasoconstrictor tone in prehypertensive adults

Brian R Weil1, Christian M Westby, Jared J Greiner

  • 1Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder, CO 80309, USA.

Insights

Elevated endothelin-1 (ET-1) vasoconstrictor tone in prehypertension impairs blood vessel dilation. This ET-1 activity contributes to the increased cardiovascular disease risk associated with prehypertension.

Area of Science:

  • Cardiovascular Physiology
  • Vascular Biology
  • Endocrinology

Background:

  • Prehypertension (BP 120-139/80-89 mm Hg) is a significant risk factor for developing hypertension and cardiovascular disease.
  • The role of endothelin (ET)-1-mediated vasoconstrictor tone in prehypertension remains unclear.
  • Investigating ET-1's contribution to endothelial dysfunction in prehypertension is crucial for understanding disease progression.

Purpose of the Study:

  • To determine if ET-1 vasoconstrictor tone is elevated in adults with prehypertension.
  • To assess whether ET-1-mediated vasoconstriction contributes to endothelial vasodilator dysfunction in this population.

Main Methods:

  • Forearm blood flow responses to selective ET(A) receptor blockade (BQ-123) were measured in normotensive and prehypertensive adults.
  • Nonselective ET-1 receptor blockade (BQ-123 + BQ-788) was assessed in a subset of participants.
  • Endothelium-dependent vasodilation to acetylcholine was evaluated with and without ET(A) receptor blockade.

Main Results:

  • Prehypertensive adults exhibited a significantly greater increase in forearm blood flow following ET(A) receptor blockade compared to normotensive adults.
  • Nonselective ET-1 blockade further increased blood flow in prehypertensive individuals, indicating a role for ET-1.
  • Acetylcholine-induced vasodilation was impaired in prehypertensive adults and improved with ET(A) receptor blockade.

Conclusions:

  • Elevated ET-1-mediated vasoconstrictor tone is present in prehypertension.
  • This increased ET-1 activity contributes to impaired endothelium-dependent vasodilation.
  • ET-1 vasoconstriction may be a key factor underlying the heightened risk of hypertension and cardiovascular disease in prehypertensive individuals.
Abstract

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...